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Today, the phenomenon of ageing characterizes our populations, causing a
large impact in our countries, principally for the growing increase of both
incidence and prevalence of not evolutionally programmed diseases, the
age-related diseases (ARDs), including cardiovascular diseases (CVDs),
neurodegenerative diseases, metabolic diseases (i.e. insulin resistance,
diabetes and metabolic syndrome), and cancer [1]. By 2030,
approximately 20% of the population will be aged 65 or older [2]. In this
age group, ARDs, and particularly the CVDs, will result in 40% of all
deaths and rank as the leading cause [3]. On the other hand, the most
important determinant of cardiovascular health is person’s age, and
precisely the person biological age, as recently suggested in our studies
[4,5]. Accordingly, biological age seems clearly to be a better predictor of
vascular risk rather than chronological age [4,5]. This concept is supported
by key assumptions that peripheral blood leukocyte telomere content
accurately reflects that of the vascular wall and its decrease is associated
with premature vascular disease [4,5]. In fact, telomere shortening is
currently considered the best ageing biomarker, but is also a predictor for
ARDs, including CVDs [4,5]. A progressive impairment of the cellular
processes (i.e. mitochondrial dysfunction, telomere attrition, genomic
instability and epigenetic alterations; see Fig.4 of review from Balistreri
and co-workers [6]), regulating cardiac and vascular homeostasis,
characterizes the vascular ageing, causing as long term effects,
endothelium dysfunction, medial degeneration, vascular remodeling and
dysfunction [7,8]. They represent pathological entities significantly
associated with the onset of a large CVD panel, but also of other ARDs.
Endothelium dysfunction is the first pathological condition associated not
only with all CVDs, but also with other ARDs, being the endothelial cells
(ECs) components of the stroma of all tissues, organs, and the niches of
adult stem cells (ASCs) [9]. This last favors the ASC senescence and
increases their susceptibility to neoplastic transformation and onset of
cancer (i.e. myeloid leukemia), and it temporally reduces their ability to
self-repair and regeneration of tissues and organs by facilitating the onset
of degenerative diseases, such as CVDs and neurodegenerative diseases
[6,9,10].
This current reality of our countries, it is becoming an obsession for both
scientific community and institutions/organizations. The first has focused
its goal in understanding the biology of ageing and ARDs, and to translate
the potential scientific insights obtained into effective interventions, in
order to improve the health in old ages and to retard and/or to delay the
onset of ARDs. The second are promoting health promotion’s programs. In
particular, among the researchers is strong opinion that the solution, to
counteract the ARD onset has the roots in the cellular mechanisms and
evolutionally conserved signaling pathways of the cells, as the stem and
progenitor cells (i.e. hematopoietic and no-hematopoietic stem cells and
their progenitors), involved in the genesis of all tissues, organs and
systems [11]. This is in accordance to the innovative concepts of fetal
programming-imprinting based on theory popularized, for the first time in
1989, by Dr David Barker, and defined as “the fetal origin of adult disease
(FOAD)”, as stressed and emphasized in our recent papers, and the
emerging concept of maternal imprinting and its influence in fetal
developing, programming and fate in adult age [amply quoted in 11
reference]. Based on these observations, the field of stem cell biology and
evolutionally conserved signaling pathways (i.e. Notch, TLR-4 and others)
is becoming the gold object of research of a large number of studies [6,11].
Conserved signaling pathways seem to mediate a double role in adult
tissues, organs and systems, contributing of their homeostasis, but also the
onset of their diseases, such as ARDs. A model has been proposed of our
group in recent papers [6,11].
Temporally, this growing research in effective therapies and interventions
is becoming a very business for several biotechnological companies,
which are promoting a growing number of therapeutic approaches as anti-
ageing and anti-ARD treatments, ranging from oxidant drugs, hormones,
vitamins and diet supplements to various aesthetic drugs and techniques.
In fact, these approaches are particularly costly for gullible patients in
searching of well-being and abused by a carefully organized marketing
involving tacit complicity of doctors, laboratories and companies [12].
However, the major number of these treatments until now constitute more
a palliative care than a very “long-life elixir”, which has long represented
for humans a dream, a vanity’s sin for remaining young and to long
survive [12]. This leads to the extemporaneous consideration that the way
for developing effective anti-ageing and anti-inflamm-ageing treatments in
humans is distant. Despite this, there is among the ageing’s researchers the
optimistic hope in identifying successful treatments and approaches for
humans too. It derives from the increase of lifespan observed in short-lived
model organisms (i.e. yeast, worm, fillies, mice and rats) undergone to
various genetic, dietary, and pharmacological interventions [12]. In
addition, some of these treatments have also demonstrated to retard the
onset of ARDs and consequently to extend the health-span (i.e. the length
of time one lives in good health), as evidenced in 2014 by Kennedy and
co-workers [13]. Thus, it is possible to affirm that this evidence in animal
models leads to the promise to develop effective life-extending
interventions in humans too. Recently, different approaches are emerging
ranging from pharmacological targeting of ageing, basic biological assays,
big data analysis to the recent use of young blood, metformin and
melatonin treatments, nutritional approaches, stem cells, cellular, genetic
and epigenetic reprogramming or other techniques of regenerative
medicine. Thus, a large number of potential anti-ageing interventions
currently exist, but only a little fraction has the features for its testing in
clinical applications [14].
In addition, it is emerging the necessity to developing different treatments
or interventions for male and female individuals in old age, and
particularly for female subjects. For example, accruing evidence indicates
that women and men experience the diabetes and CVDs differently and it
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has been also observed that the relative risk for fatal ischemic heart disease
associated with diabetes is 50% higher in women than in men [15]. Thus,
sex dimorphism determines a complex pathological picture in onset of these
ARDs, and in women it is exacerbated by the complex interaction among
genetic, hormonal and environmental factors, as described in 2005 by
Mendelsohn and Karas in Science journal [16] and stressed in our paper
[15]. Regarding the role of genetic factors, studies on sex chromosomes,
their gene content and the related disease risk are emerging. Wiham and co-
workers are recently summarized some new literature data and stressed that
CVDs, as well as diabetes, represent complex genetic traits with phenotypes
influenced by genetic, hormonal, environmental, and cultural variables [17].
Thus sex differences must be considered in the future investigations and the
development of effective therapies and preventive approaches.
We recently suggested that each individual is the result of the sophisticated
interplay between environmental factors and its genome, trascriptome,
proteome, metabolome, microbiome, epigenome, exposome [6,18]. Thus, it
is necessary to perform a more complex combination of investigations
based on genetic, transcriptomic, proteomic, metabolomic, microbiomic
and epigenetic evaluations, for obtaining interesting data in the study of
these diseases. In addition, computational investigations are also
recommended, as well as collecting environmental and biometric data,
medical/scientific/health care records [6,18]. Thus, we have proposed that
the integration of all data, obtained in this large panel of investigations, and
their elaboration might lead to the development of appropriate agonists,
antagonists, inhibitors of specific signaling disease pathways, which might
be used in a near future as personalized treatments for these diseases,
facilitating their management and outcome [6,18]. Thus, the solution might
be in looking with new eyes the goal of ageing and ARD research in order
to make new discoveries, although, the ways to execute still are long and
difficult [18].
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